ID: ALA5266503

Max Phase: Preclinical

Molecular Formula: C11H7ClN4

Molecular Weight: 230.66

Associated Items:

Representations

Canonical SMILES:  N#Cc1cc(-c2ccc(N)nc2)cnc1Cl

Standard InChI:  InChI=1S/C11H7ClN4/c12-11-8(4-13)3-9(6-16-11)7-1-2-10(14)15-5-7/h1-3,5-6H,(H2,14,15)

Standard InChI Key:  HOTVBPKZXBNYFL-UHFFFAOYSA-N

Associated Targets(Human)

PI3-kinase p110-delta subunit 6699 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 230.66Molecular Weight (Monoisotopic): 230.0359AlogP: 2.25#Rotatable Bonds: 1
Polar Surface Area: 75.59Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 6.24CX LogP: 1.63CX LogD: 1.60
Aromatic Rings: 2Heavy Atoms: 16QED Weighted: 0.76Np Likeness Score: -0.64

References

1. Yang C, Gong Y, Gao Y, Deng M, Liu X, Yang Y, Ling Y, Jia Y, Zhou Y..  (2023)  Design, synthesis and in vitro biological evaluation of 2-aminopyridine derivatives as novel PI3Kδ inhibitors for hematological cancer.,  82  [PMID:36706844] [10.1016/j.bmcl.2023.129152]

Source